home All News open_in_new Full Article

Aptose Common Shares to Delist from Nasdaq as of April 2, 2025

SAN DIEGO and TORONTO, April 01, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced that the Nasdaq Hearings Panel (the “Panel”) has determined […]


today 31 h. ago attach_file Other

attach_file Economics
attach_file Culture
attach_file Other
attach_file Culture
attach_file Culture
attach_file Other
attach_file Other


ID: 2045030360
Add Watch Country

arrow_drop_down